Jordan Alana Ciuro, MD, assistant professor of medicine at Winship Cancer Institute at Emory University, shares key abstracts and topics from the upcoming 2025 ASCO GU Symposium. Dr. Ciuro highlights the latest research in biomarker-driven oncology, prostate cancer treatment advancements, kidney cancer disparities, and emerging therapies in bladder cancer. Key trials, including TALAPRO-2, COSMIC-313, and EV-302, are explored, along with insights into antibody-drug conjugates and their evolving role in GU cancers.
ASCO GU Preview: Prostate, Bladder, and Kidney Cancer Research to Monitor
By Jordan Ciuro, MD - Last Updated: February 12, 2025Related Posts
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT
Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.